A randomised, placebo controlled study of alfuzosin in patients undergoing trial without catheter following admission with acute urinary retention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN36163730

Enrollment

Registered

2003-09-12

Start date

1998-01-01

Completion date

Unknown

Last updated

2020-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Signs and Symptoms: Acute urinary retention Signs and Symptoms Acute urinary retention

Interventions

Randomised, placebo-controlled study at two centres. The aim of the study is to evaluate the effectiveness of alpha-adrergic blocker alfuzosin SR 5 mg given to patients in acute urinary retention prio

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with acute urinary retention who meet inclusion criteria

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Successful outcome will be measured in terms of spontaneous voiding	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026